Cargando…
The EU Response to the Presence of Nitrosamine Impurities in Medicines
The unexpected detection of nitrosamine impurities in human medicines has recently seen global regulators act to understand the risks of these contaminations to patients and to limit their presence. Over 300 nitrosamines are known, many of which are highly potent mutagenic carcinogens. Regulators fi...
Autores principales: | Ruepp, Robin, Frötschl, Roland, Bream, Robert, Filancia, Maria, Girard, Thomas, Spinei, Andrei, Weise, Martina, Whomsley, Rhys |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641785/ https://www.ncbi.nlm.nih.gov/pubmed/34869504 http://dx.doi.org/10.3389/fmed.2021.782536 |
Ejemplares similares
-
Presence of Nitrosamine Impurities in Medicinal Products
por: Sedlo, Ilijana, et al.
Publicado: (2021) -
Collaborative reliance in medicine safety and quality regulation: Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries
por: Shabangu, Patience P., et al.
Publicado: (2022) -
Development and Validation of four Nitrosamine Impurities Determination Method in Medicines of Valsartan, Losartan, and Irbesartan with HPLC-MS/MS (APCI)
por: Khorolskiy, Mikhail, et al.
Publicado: (2021) -
Practical and
Science-Based Strategy for Establishing
Acceptable Intakes for Drug Product N-Nitrosamine
Impurities
por: Dobo, Krista L., et al.
Publicado: (2022) -
Hyperfine interaction of Eu impurities implanted in nickel
por: Niessen, L, et al.
Publicado: (1990)